(NASDAQ: SNGX) Soligenix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 62.74%.
Soligenix's earnings in 2026 is -$10,239,455.On average, 4 Wall Street analysts forecast SNGX's earnings for 2026 to be -$10,545,375, with the lowest SNGX earnings forecast at -$11,731,593, and the highest SNGX earnings forecast at -$9,141,501. On average, 4 Wall Street analysts forecast SNGX's earnings for 2027 to be -$7,215,256, with the lowest SNGX earnings forecast at -$8,532,068, and the highest SNGX earnings forecast at -$5,713,438.
In 2028, SNGX is forecast to generate -$8,436,300 in earnings, with the lowest earnings forecast at -$8,105,464 and the highest earnings forecast at -$8,684,426.